PSMA Targeted Therapy Pipeline Review 2025 | Competitor Insights and R&D Progress in PSMA Therapeutics - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "PSMA - Targeted Therapy Pipeline Review" report has been added to ResearchAndMarkets.com's offering.

This report provides information on approved therapeutics and therapy candidates in research and development targeting PSMA.

This product consists of:

• Competitors described in a tabular format covering drug code/INN, target(s)/MoA, class of compound, product category, indication(s) & R&D stage.
• Project History with links to source of information (press release, homepage, abstracts, presentations, annual reports etc).
• One-month online access to a database for therapeutics and therapy candidates targeting PSMA (prerequisite: access to internet).

In addition to androgen deprivation therapy (ADT), there have been a number of therapies approved in the mCRPC setting over the past two decades, including taxane chemotherapy (docetaxel and cabazitaxel), immunotherapy (sipuleucel-T and pembrolizumab), androgen receptor pathway inhibitors (ARPIs; abiraterone and enzalutamide), and targeted therapies such as poly (ADP-ribose) polymerase (PARP) inhibitors (olaparib and rucaparib).

Despite the increasing size of this armamentarium, the vast majority of patients with CRPC progress and novel agents are urgently needed to improve survival while maintaining quality of life.

Prostate specific membrane antigen (PSMA) expression is prevalent in prostate cancer, preserved during malignant transformation, and increases in response to anti-androgen therapies, making it a commonly targeted tumor associated antigen for prostate cancer. PSMA mainly serves as a binding target for delivery of a variety of payloads, including, but not limited to, cytotoxic drugs in antibody-drug conjugtes, recruitment of cytotoxic T-cells in bispecific antibodies or directly PSMA-targeted chimeric antigen receptor T-cells.

PSMA is also an important binding target for delivery of radioactive payloads in targeted radioligand therapy, whereby binding molecules can be small molecules, peptides and antibodies.

A variety of radioligands are being evaluated or already been approved, including lutetium 177, actinium 225, thorium 227, cupper 67, or iodine 131.

For more information about this report visit https://www.researchandmarkets.com/r/6qdtkf

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.